anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In a first embodiment, a hydraulically-formed nonwoven sheet, a package comprising such sheet, a method of packaging a medical device using a package with such sheet and a method of manufacturing such sheet are provided. This nonwoven sheet comprises first and second non-cellulosic polymeric fibers. The first non-cellulosic polymeric fibers have an average diameter less than about 3.5 micron, an average cut length less than about 3 millimeters and an average aspect ratio of about 400 to about 2000; the second non-cellulosic polymeric fibers have an average diameter greater than about 3.5 micron and an average aspect ratio of about 400 to about 1000. In a second embodiment, a hydraulically-formed nonwoven sheet is provided. This nonwoven sheet comprises binding material, non-cellulosic polymeric fibers and cellulosic based materials. The non-cellulosic polymeric fibers have an average diameter less than about 3.5 micron, an average cut length less than about 3 millimeters and an averag e aspect ratio of about 400 to about 2000. The second nonwoven sheet has a bacterial filtration efficiency of at least about 98%.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, oncology, and can be used for combination treatment of locally advanced operable oesophageal cancer. That is ensured by 2 preoperative courses of polychemotherapy under the regimen: cisplatin 50 mg/m2 on the 1st, 8th day, gemcitabine 800 mg/m2 intravenously drop-by-drop in a infusion of half an hour's duration - on the 2nd, 9th days every 3 weeks. In 3 weeks, it is followed with a radical surgery with two-regional lymphodissection. Thereafter, the surgery involves an IRT (intraoperative radiation therapy) session in a single dose 10 Gy on an extracted tumour bed and a regional metastasis path. ^ EFFECT: method allows higher effectiveness of the combination treatment of the patients with operable oesophageal cancer, prevented progressing tumour process and remote metastasis, and also reduced number of postoperative complications due to reduced dysphagia effect and maintained preoperative complete nutrition of the patient without gastrostoma. ^ 1 ex
<P>PROBLEM TO BE SOLVED: To provide a solid-liquid separator suitable for obtaining juice by squeezing plants such as shell ginger, and capable of effectively squeezing shell ginger or the like and efficiently distilling squeezed juice.  <P>SOLUTION: The separator has a drive source to rotate a screw so as to press and move hydrate fed in a cylindrical body having the screw from one end to the other. The separator has a feeding unit to feed the hydrate on one end side of the cylindrical body, and a discharge port for solids with water separated therefrom on the other end side. A large number of small holes for passing the squeezed juice are opened in a side wall of the cylindrical body. The position of a lid body movable in the axial direction of the screw can be continuously or intermittently selected near the discharge port.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A 6-weeks prospective randomized controlled trial examined the effects of core stabilization exercise (CSE) plus kinesio taping (KT) compared to CSE alone on pain, fatigue, health status, quality of life, sleep quality and depression in woman with FM. The trial was approved by the Ethics committee of Ankara Yildirim Beyazit University (Approval time and number: 17.01.2018-14). The study was performed in compliance with Helsinki Declaration where applicable. The patient's recruitment started in February 2018. The patients diagnosed with Fibromyalgia according to the criteria of the 1990 American College of Rheumatology participated in the study. Prior to the treatment and after 6-weeks treatment, participants' pain level, fatigue, health status, quality of life (QoL), psychological status and sleep quality were assessed. Assessments were realized by face-to-face interview method.Patients who participated in CSE group performed CSE program alone, whereas patients in CSE+KT group performed CSE program with KT application. The treatment was carried out 2 days a week for 6 weeks.
The invention discloses an anti-insulin-like growth factor receptor (IGF-1R) human-sourced functional antibody LMAb1 which is prepared through an antibody library technology. The preparation method includes the following steps: obtaining the antibody through molecular biology and the like technologies, constructing the antibody to a eukaryotic expression vector and performing transient transfection to obtain the antibody. The antibody is subjected to biological function detection through flow cytometry, cell proliferation inhibition, cell migration, clone formation, in-vivo tumor inhibition and the like. An in-vitro test proves that the LMAb1 can be combined with membrane IGF-1R to effectively kill IGF-1R positive cells and inhibit tumor cell migration and clone formation. An in-vivo test result proves that the LMAb1 can inhibit growth of tumors and prolong survival life of mice. The invention also discloses a sequence and the preparation method of the antibody.
This study aimed to assess if transient bacteremia developed from dental scaling, root planing (SRP) and dental extraction(s), if the bacteria originated from oral flora, and if the amount of bacteremia produced would warrant the use of pre-, intra-, or post-operative antibiotic therapy in healthy canine patients. Blood cultures were obtained from 13 healthy dogs with chronic periodontal disease that necessitated the extraction of one tooth or multiple teeth. Patients included did not receive any antibiotic therapy for a minimum of 2 weeks prior to their scheduled procedure and did not receive antibiotic therapy intra- or post-operatively. Blood collection occurred at specific time increments to determine the presence of bacteremia and if clearance of the bacteremia occurred post-procedure. The study found transient bacteremia developed at different time increments throughout the dental procedure. At the time of the final sample collection, no bacterial growth was evident in any of the blood cultures. Results of the blood cultures indicated that only four of 13 dogs had evidence of bacterial growth at any one of the time increments; however, by the final collection, there was no bacterial growth suggesting the transient bacteremia had cleared without the use of systemic antimicrobial therapy. The study findings indicate that systemic antibiotic usage is not warranted for severe periodontal disease where an episode of transient bacteremia is produced from SRP and dental extractions in an otherwise healthy patient.
BACKGROUND: Long-chain PUFA (LC-PUFA) influence varying aspects of inflammation. One mechanism by which they regulate inflammation is by controlling the size and molecular composition of lipid rafts. Lipid rafts are sphingolipid/cholesterol-enriched plasma membrane microdomains that compartmentalize signaling proteins and thereby control downstream inflammatory gene expression and cytokine production.
OBJECTIVES: This review summarizes developments in our understanding of how LC-PUFA acyl chains of phospholipids, in addition to oxidized derivatives of LC-PUFAs such as oxidized 1-palmitoyl-2-arachidonyl-phosphatidylcholine (oxPAPC), manipulate formation of lipid rafts and thereby inflammation.
METHODS: We reviewed the literature, largely from the past 2 decades, on the impact of LC-PUFA acyl chains and oxidized products of LC-PUFAs on lipid raft biophysical organization of myeloid and lymphoid cells. The majority of the studies are based on rodent or cellular experiments with supporting mechanistic studies using biomimetic membranes and molecular dynamic simulations. These studies have focused largely on the LC-PUFA docosahexaenoic acid, with some studies addressing eicosapentaenoic acid. A few studies have investigated the role of oxidized phospholipids on rafts.
RESULTS: The biophysical literature suggests a model in which n-3 LC-PUFAs, in addition to oxPAPC, localize predominately to nonraft regions and impart a disordering effect in this environment. Rafts become larger because of the ensuing increase in the difference in order between raft and nonrafts. Biochemical studies suggest that some n-3 LC-PUFAs can be found within rafts. This deviation from homeostasis is a potential trigger for controlling aspects of innate and adaptive immunity.
CONCLUSION: Overall, select LC-PUFA acyl chains and oxidized acyl chains of phospholipids control lipid raft dynamics and downstream inflammation. Gaps in knowledge remain, particularly on underlying molecular mechanisms by which plasma membrane receptor organization is controlled in response to oxidized LC-PUFA acyl chains of membrane phospholipids. Validation in humans is also an area for future study.
Rituximab, 375 milligram per meter square (mg/m\^2) was given intravenously on Day 1 and then every 28 days (+/-7 days) for 6 cycles, followed by 2 consolidated infusions in responders as rituximab induction therapy. Rituximab infusions were administered concomitantly with prescribed chemotherapy i.e., fludarabine, cyclophosphamide and mitoxantrone (maximum 6 cycles).
INDOCIN (indomethacin) Oral Suspension is a nonsteroidal anti-inflammatory drug, available as an oral suspension contain 25 mg of indomethacin per 5mL, alcohol 1%, and sorbic acid 0.1% added as a preservative for oral administration. The chemical name is -(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. The molecular weight is 357.8. Its molecular formula is C19H16ClNO4 , and it has the following chemical structure. 

Indomethacin is a white to yellow crystalline powder. It is practically insoluble in water and sparingly soluble in alcohol. Indomethacin has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali. The suspension has a pH of 4.0-5.0. 

The inactive ingredients in INDOCIN include: antifoam AF emulsion, flavors, purified water, sodium hydroxide or hydrochloric acid to adjust pH, sorbitol solution, and tragacanth. INDOCIN Oral Suspension, 25 mg per 5 mL, is an off-white suspension with a pineapple coconut mint flavor.
In this group, younger adults (18-64) and older (from 65 and older) from the general population are included. The participants fill in questionnaires.
Patients older than 20 years were recruited from the Glaucoma Clinic of National Taiwan University Hospital. Patients were considered eligible for enrolment if they were newly diagnosed with glaucoma and started to receive ocular hypotensive eye drops at our clinic. Eligible patients then received 0.03% bimatoprost (preservative-free) (Lumigan PF, Allergan Inc., CA, USA).
There is few data on the stability of these antibodies, most of the studies are cross-sectional. There are conflicting results among scarce longitudinal data. One study reported a negativation of anti-glycan antibodies in some cases but not of ASCA or ANCA.

On the cohort of 195 patients included in the first study, the investigator would like to assess at 3 years the immunological profiles of these patients and thus to compare them. In case of modification of the serological status for some antibodies, the search for associated factors (clinical, biological or therapeutic) will be performed. In case of sero-negativation of anti-glycan antibodies, this could be linked with a decrease or a normalization of the increased intestinal permeability in IBD. Indeed, in this subgroup of patients, we will test this hypothesis by analyzing intestinal permeability in anti-glycan positive group on the 2 samples and in the group with a sero-negativation on the second sample.
the aim of this study was to clinically evaluate the effect on secondary wound healing of the topical application of hyaluronic acid to the surgical field after frenectomy operation performed with laser, through evaluation of the amount of reduction of the wound site and postoperative pain levels.The study included a total of 40 patients who had maxillary high labial frenulum attachment and were planned to undergo frenectomy and met the study inclusion criteria. All the patients were informed about oral hygiene control and attention was paid that optimal oral hygiene was maintained throughout the study. Phase I periodontal treatment was applied to patients where necessary. The area measurements of the wound site formed after frenectomy was taken immediately after the frenectomy and on days 3, 7, and 21 postoperatively. HA gel was applied topically after the frenectomy operation to the test group and not to the control group. All the surgical procedures were performed by the same surgeon.
Patients with PTEN loss receive copanlisib IV over 1 hour on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
FIELD: medicine; pharmaceuticals.SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and is intended to maintain stability of dibutylhydroxytoluene in a liquid preparation. Ophthalmic product in the form of a container contains a liquid preparation containing dibutylhydroxytoluene, pranoprofen and/or a pharmaceutically acceptable salt thereof and at least one compound selected from a group consisting of a chondroitin sulphate ester, aspartic acid, alginic acid, alginic acid derivative and their pharmaceutically acceptable salts and cyanocobalamin, panthenol, tocopherol and tocopherol derivative. Components are used in claimed amounts. Container comprises a housing, a nozzle having an outlet, and a cap for closing the outlet. At least one of the surfaces of the walls of the inner space of the spout and the surfaces of the cap walls facing the outlet has a resin which contains polybutylene terephthalate. Also provided is a method of stabilizing dibutylhydroxytoluene in a liquid preparation.EFFECT: use of the group of inventions makes it possible to increase thermal stability of dibutylhydroxytoluene and to suppress reduction of its content over time in the liquid preparation.16 cl, 8 tbl, 6 dwg, 5 ex
An embodiment of an ingestible device for the delivery of a therapeutic agent includes a swallowable outer shell and a delivery mechanism within the outer shell. The delivery mechanism includes an expandable enclosure. The delivery mechanism is triggerable in situ within a gastrointestinal (GI) tract of a body to expand multiple regions of the expandable enclosure to an expanded state at a delivery location within the body. The multiple regions include a head region and a tail region with a protective recess defined between the head region and the tail region, and a retention region within the protective recess. A dimension of the retention region as expanded is less than a dimension of the head region as expanded and less than a dimension of the tail region as expanded. The ingestible device includes a shaped composition disposed at the retention region.
BACKGROUND: The aim of this study was to evaluate the effectiveness of the intravenous, oral and local application of tranexamic acid in operation time, intraoperative bleeding, postoperative edema and ecchymosis in rhinoplasty.
METHODS: This was a randomized, double-blinded, prospective study. We included 146 patients who underwent rhinoplasty at the Bezmialem Vakif University Medical Faculty Otorhinolaryngology Clinic between April 2021 and April 2022. The patients were divided into four groups: Group 1 (intravenous TXA), Group 2 (oral TXA), Group 3 (topical TXA), and Group 4 (control). Operation time was recorded. Bleeding volume was measured in the suction chamber and nasopharyngeal pack. Postoperative edema and ecchymosis were evaluated using a scale at the end of the operation, on the 1st, 3rd, and 7th days.
RESULTS: There was no statistically significant difference between groups in terms of mean operation time (p = 0.894). There was a statistically significant lower mean intraoperative bleeding level in Group 2 from the other groups (p = 0.020). Group 3 had significantly lower scores for postoperative edema than the other groups at the end of the operation, on the 1st, 3rd, and 7th days (p < 0.05), and significantly lower scores for postoperative ecchymosis at the end of the operation (p = 0.013) and on the 3rd day (p = 0.024). Although group 3 had a lower score than the other groups in the ecchymosis measurements on the 1st, and 7th days, no statistically significant results were obtained.
CONCLUSIONS: Local application of tranexamic acid is founded more beneficial for reducing postoperative edema and ecchymosis in rhinoplasty than intravenous and/or oral applications in this study.
LEVEL OF EVIDENCE I: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Breast cancer patients with initial axillary metastasis（T1-3N1-3M0） who are preparing for neoadjuvant therapy(NAT)，including neoadjuvant chemotherapy, targeted therapy, immunotherapy, etc. will received imaging examination（MRI、mammography、ultrasonography）at baseline and after every two cycles of NAT before surgery, dedicated breast/lymph positron emission tomography(DB/L-PET) at baseline and after first 1-2 cycle of NAT. We have developed a prediction model, which includes clinical parameters, pathological parameters, imaging examination parameters and DB/L-PET to predict the probability of complete pathological remission of axillary lymph nodes after receiving NAT. If the probability is more than 90%, the process of axillary surgical evaluation will be spared. If the probability is 50% -90%, Sentinel lymph node biopsy will be performed. If the probability is less than 50%, standard axillary lymph node dissection will be performed.
TE HCV GT3 participants will take 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.
The invention relates to a novel antibacterial peptide DN6NH 2 And applications thereof. Antibacterial peptide DN6NH 2 Is obtained by amidation modification of carboxyl at the C terminal of antibacterial peptide N6, and the other amino acids except glycine are D-type amino acids. Antibacterial peptide DN6NH 2 Can obviously improve the parent peptide N6NH 2 Has the characteristics of quick sterilization and no rebound sterilization on multiple drug-resistant Aeromonas veronii, and has low cytotoxicity and low hemolysis. DN6NH 2 Can inhibit the formation of aeromonas veronii biofilm in vitro; in vivo, the composition can obviously improve the phenomenon of back skin abscess necrosis of mice caused by infection of Aeromonas veronii biomembranes, and the effect is superior to that of parent peptide and ciprofloxacin. The experimental result shows that DN6NH 2 Obviously improves N6NH 2 The enzymatic stability and the biological activity of the compound. Antibacterial peptide DN6NH 2 Is a micromolecular polypeptide with great application value and has wide application prospect.
H2N2 influenza viruses emerged in the 1950s replacing the then circulating H1N1 human influenza virus. The first cases occurred in China in 1956, and disease became widespread in 1956-1957, resulting in the "Asian Influenza" pandemic that was responsible for between 1 and 4 million deaths worldwide. H2N2 viruses have not circulated since 1968, when they were replaced by H3N2 influenza viruses and the resurgence of H1N1 viruses. For this reason, a large proportion of the population is now susceptible to infection with H2N2 influenza. If this subtype re-emerges, it could potentially cause the next pandemic. This vaccine, therefore, is an important priority in the development of vaccines against potential pandemic influenza strains.

This vaccine trial will be conducted in the Center for Immunization Research isolation unit in the Mason F. Lord Building at the Johns Hopkins Bayview Medical Center (Baltimore, MD). The study will be initiated between April 1st and December 20th, 2008, when wild-type influenza is unlikely to be circulating in the Baltimore area.

An individual's participation in the study will last approximately 90 days. All participants will receive two vaccinations approximately 4 - 8 weeks apart. After each vaccination, participants will remain in isolation at the study site for at least nine days or until rRT-PCR assays for influenza are negative for 2 consecutive days. A physical examination and nasal wash will occur each day during the isolation period. Blood collection will occur in isolation beginning on Day 7 until release. Follow-up outpatient visits are scheduled on Days 28 and 56 after the first vaccination and on Day 28 after the second vaccination. Follow-up visits will include serum collection, nasal wash, and interim medical history.
BACKGROUND: SPEAK OUT! has been shown to enhance various aspects of voice such as intensity, prosody, voice quality and perception of voice. However, their impacts on expiration and communication effectiveness have not yet been evaluated. This study aimed to evaluate the effectiveness of the Hybrid SPEAK OUT! method on aerodynamic measurements and patient-reported outcome measures (PROMs) in individuals with Parkinson's disease (PD).
METHODS: This study included 157 participants with PD who underwent an intensive 8-week multidisciplinary treatment program. The Hybrid SPEAK OUT! method consisted of three sessions per week, including two group sessions and one individual treatment session. Voice-related aerodynamic measures included maximum phonation time (MPT), vocal cord function using the S/Z ratio, and expiratory flow measures including peak expiratory flow (PEF) and peak cough flow (PCF). Two PROMs were included: the Hebrew version of the voice handicap index-10 and communication effectiveness questionnaire.
RESULTS: The results of 111 participants were analysed. MPT duration increased, PEF and PCF increased, and better scores were found in PROMs.
CONCLUSION: These findings would appear to support the effectiveness of the Hybrid SPEAK OUT! methods improving function, activity and participation in individuals with PD. However, further research is needed.
WHAT THIS PAPER ADDS: What is already known on the subject Prior research has demonstrated the effectiveness of behavioral therapies, including the SPEAK OUT! program, in managing speech symptoms in individuals with Parkinson's disease (PD). These therapies have shown improvements in voice intensity, fundamental frequency, voice quality, and voice perception. However, the impact on aerodynamic measures, expiratory flow, and patient-reported outcome measures has not been extensively studied. What this paper adds to existing knowledge This study adds to the existing knowledge by demonstrating that a Hybrid SPEAK OUT! approach, can lead to improvements in aerodynamic measures, including maximum phonation time (MPT), expiratory and cough peak flow. In terms of motor learning, we found that two non-speech exhalation-related tasks that were not directly trained improved following the intensive speech training protocol. Furthermore, it shows positive changes in patient-reported outcome measures, with reduced voice-related disability and improved communication efficiency. What are the potential or actual clinical implications of this work? The findings of this study have important clinical implications for the management of speech symptoms in individuals with PD. The Hybrid SPEAK OUT! program, which combines group and individual sessions, can effectively improve voice, aerodynamic measurements and patient-reported outcome measures (PROMs), ultimately enhancing the overall quality of life for patients. These findings support the effectiveness of the Hybrid SPEAK OUT! methods for improving function, activity, and participation in individuals with PD.